Education

Ph.D in Ecole Doctorale de Cancérologie, Institut Gustave Roussy, Université Paris-Sud 11, France, 2011

Current Position

Principal Investigator, PhD mentor in Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences, China

Publications

1. Vacchelli, E., Ma, Y., Baracco, E. E., Zitvogel, L. and Kroemer, G. (2016). Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. Oncoimmunology 5(5): e1118600.
2. Ma, Y., Yang, H., Pitt, J. M., Kroemer, G. and Zitvogel, L. (2016). Therapy-induced microenvironmental changes in cancer. J Mol Med (Berl) 94(5): 497-508.
3. Yang, H., Ma, Y., Chen, G., Zhou, H., Yamazaki, T., Klein, C., Pietrocola, F., Vacchelli, E., Souquere, S., Sauvat, A., Zitvogel, L., Kepp, O. and Kroemer, G. (2016). Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology 5(6): e1149673.
4. Yang, H., Yamazaki, T., Pietrocola, F., Zhou, H., Zitvogel, L., Ma, Y. and Kroemer, G. (2016). Improvement of immunogenic chemotherapy by STAT3 inhibition. Oncoimmunology 5(2): e1078061.
5. Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Gunther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., Andre, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L. and Kroemer, G. (2015). Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350(6263): 972-978.
6. Yang, H., Yamazaki, T., Pietrocola, F., Zhou, H., Zitvogel, L., Ma, Y. and Kroemer, G. (2015). STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. Cancer Res 75(18): 3812-3822.
7. Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Portela Catani, J. P., Duret, H., Teng, M. W., Kepp, O., Wang, Y., Sistigu, A., Schultze, J. L., Stoll, G., Galluzzi, L., Zitvogel, L., Smyth, M. J. and Kroemer, G. (2014). CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 74(2): 436-445.
8. Ma, Y., Adjemian, S., Galluzzi, L., Zitvogel, L. and Kroemer, G. (2014). Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. Oncoimmunology 3(1): e27663.
9. Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Metivier, D., Galluzzi, L., Perfettini, J. L., Zitvogel, L. and Kroemer, G. (2014). Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21(1): 79-91.
10. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remedios, C., Fend, L., Hannani, D., Aymeric, L., Ma, Y., Niso-Santano, M., Kepp, O., Schultze, J. L., Tuting, T., Belardelli, F., Bracci, L., La Sorsa, V., Ziccheddu, G., Sestili, P., Urbani, F., Delorenzi, M., Lacroix-Triki, M., Quidville, V., Conforti, R., Spano, J. P., Pusztai, L., Poirier-Colame, V., Delaloge, S., Penault-Llorca, F., Ladoire, S., Arnould, L., Cyrta, J., Dessoliers, M. C., Eggermont, A., Bianchi, M. E., Pittet, M., Engblom, C., Pfirschke, C., Preville, X., Uze, G., Schreiber, R. D., Chow, M. T., Smyth, M. J., Proietti, E., Andre, F., Kroemer, G. and Zitvogel, L. (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20(11): 1301-1309.
11. Rao, S., Tortola, L., Perlot, T., Wirnsberger, G., Novatchkova, M., Nitsch, R., Sykacek, P., Frank, L., Schramek, D., Komnenovic, V., Sigl, V., Aumayr, K., Schmauss, G., Fellner, N., Handschuh, S., Glosmann, M., Pasierbek, P., Schlederer, M., Resch, G. P., Ma, Y., Yang, H., Popper, H., Kenner, L., Kroemer, G. and Penninger, J. M. (2014). A dual role for autophagy in a murine model of lung cancer. Nat Commun 5: 3056.
12. Sukkurwala, A. Q., Martins, I., Wang, Y., Schlemmer, F., Ruckenstuhl, C., Durchschlag, M., Michaud, M., Senovilla, L., Sistigu, A., Ma, Y., Vacchelli, E., Sulpice, E., Gidrol, X., Zitvogel, L., Madeo, F., Galluzzi, L., Kepp, O. and Kroemer, G. (2014). Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 21(1): 59-68.
13. Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., Martins, I., Schlemmer, F., Michaud, M., Kepp, O., Sukkurwala, A. Q., Menger, L., Vacchelli, E., Droin, N., Galluzzi, L., Krzysiek, R., Gordon, S., Taylor, P. R., Van Endert, P., Solary, E., Smyth, M. J., Zitvogel, L. and Kroemer, G. (2013). Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38(4): 729-741.
14. Ma, Y., Yamazaki, T., Yang, H., Kepp, O., Galluzzi, L., Zitvogel, L., Smyth, M. J. and Kroemer, G. (2013). Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology 2(6): e24786.
15. Ma, Y., Adjemian, S., Yang, H., Catani, J. P., Hannani, D., Martins, I., Michaud, M., Kepp, O., Sukkurwala, A. Q., Vacchelli, E., Galluzzi, L., Zitvogel, L. and Kroemer, G. (2013). ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2(6): e24568.
16. Ma, Y., Galluzzi, L., Zitvogel, L. and Kroemer, G. (2013). Autophagy and cellular immune responses. Immunity 39(2): 211-227.
17. Wang, Y., Martins, I., Ma, Y., Kepp, O., Galluzzi, L. and Kroemer, G. (2013). Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. Autophagy 9(10): 1624-1625.
18. Hannani, D., Ma, Y., Yamazaki, T., Dechanet-Merville, J., Kroemer, G. and Zitvogel, L. (2012). Harnessing gammadelta T cells in anticancer immunotherapy. Trends Immunol 33(5): 199-206.
19. Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., Schlemmer, F., Sulpice, E., Locher, C., Gidrol, X., Ghiringhelli, F., Modjtahedi, N., Galluzzi, L., Andre, F., Zitvogel, L., Kepp, O. and Kroemer, G. (2012). Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 4(143): 143ra199.
20. Kepp, O., Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Sukkurwala, A. Q., Michaud, M., Galluzzi, L., Zitvogel, L. and Kroemer, G. (2012). Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology 1(9): 1640-1642.
21. Martins, I., Michaud, M., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Shen, S., Kepp, O., Menger, L., Vacchelli, E., Galluzzi, L., Zitvogel, L. and Kroemer, G. (2012). Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 8(3): 413-415.
22. Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., Lasarte, J. J., Matsuzaki, G., Ikuta, K., Ryffel, B., Benlagha, K., Tesniere, A., Ibrahim, N., Dechanet-Merville, J., Chaput, N., Smyth, M. J., Kroemer, G. and Zitvogel, L. (2011). Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208(3): 491-503.
23. Ma, Y., Conforti, R., Aymeric, L., Locher, C., Kepp, O., Kroemer, G. and Zitvogel, L. (2011). How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 30(1): 71-82.
24. Ma, Y., Aymeric, L., Locher, C., Kroemer, G. and Zitvogel, L. (2011). The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 23(1): 146-152.
25. Andrews, D. M., Chow, M. T., Ma, Y., Cotterell, C. L., Watt, S. V., Anthony, D. A., Akira, S., Iwakura, Y., Trapani, J. A., Zitvogel, L. and Smyth, M. J. (2011). Homeostatic defects in interleukin 18-deficient mice contribute to protection against the lethal effects of endotoxin. Immunol Cell Biol 89(6): 739-746.
26. Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L. and Smyth, M. J. (2011). Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71(14): 4809-4820.
27. Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., Rello-Varona, S., Tailler, M., Menger, L., Vacchelli, E., Galluzzi, L., Ghiringhelli, F., di Virgilio, F., Zitvogel, L. and Kroemer, G. (2011). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062): 1573-1577.
28. Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., Smyth, M. J., Kroemer, G. and Zitvogel, L. (2010). Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 22(3): 113-124.
    
29. Conforti, R., Ma, Y., Morel, Y., Paturel, C., Terme, M., Viaud, S., Ryffel, B., Ferrantini, M., Uppaluri, R., Schreiber, R., Combadiere, C., Chaput, N., Andre, F., Kroemer, G. and Zitvogel, L. (2010). Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 70(2): 490-500.
30. Ma, Y., Yang, H., Qi, J., Liu, D., Xiong, P., Xu, Y., Feng, W., Zheng, G., Li, P., Fang, M., Tan, Z., Zheng, F. and Gong, F. (2010). CD2AP is indispensable to multistep cytotoxic process by NK cells. Mol Immunol 47(5): 1074-1082.
31. Heng, Y., Ma, Y., Yin, H., Duan, L., Xiong, P., Xu, Y., Feng, W., Fang, M., Tan, Z., Chen, Y., Zheng, F. and Gong, F. (2010). Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. Transpl Int 23(12): 1259-1270.
32. Zitvogel, L., Kepp, O., Aymeric, L., Ma, Y., Locher, C., Delahaye, N. F., Andre, F. and Kroemer, G. (2010). Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 70(23): 9538-9543.
33. Locher, C., Conforti, R., Aymeric, L., Ma, Y., Yamazaki, T., Rusakiewicz, S., Tesniere, A., Ghiringhelli, F., Apetoh, L., Morel, Y., Girard, J. P., Kroemer, G. and Zitvogel, L. (2010). Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 1209: 99-108.
34. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., Perfettini, J. L., Schlemmer, F., Tasdemir, E., Uhl, M., Genin, P., Civas, A., Ryffel, B., Kanellopoulos, J., Tschopp, J., Andre, F., Lidereau, R., McLaughlin, N. M., Haynes, N. M., Smyth, M. J., Kroemer, G. and Zitvogel, L. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15(10): 1170-1178.